The fight against solid tumors just got a $20.0M boost, with Waypoint Bio announcing its Series A funding round close. The VC-backed biotech startup is focused on building the next generation of cell therapies, aiming to tackle some of oncology's most challenging targets.
The investment round saw participation from a strong syndicate of firms, including Amplify Partners, General Catalyst, Time BioVentures, Lux Capital, and Hummingbird Ventures. Waypoint Bio's mission centers on developing advanced therapeutic solutions in this critical area.





.png&w=3840&q=75)








